ORKA - Oruka Therapeutics, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$153.25
DETAILS
HIGH:
$200.00
LOW:
$120.00
MEDIAN:
$155.50
CONSENSUS:
$153.25
UPSIDE:
85.44%
About Oruka Therapeutics, Inc. (http://www.orukatx.com)
Oruka Therapeutics, Inc. functions as a biotechnology firm primarily dedicated to creating groundbreaking monoclonal antibody therapies. These treatments are designed to address Psoriasis (PsO) along with various other inflammatory and immunological (I&I) conditions. Its current development portfolio includes ORKA-001 and ORKA-002. The company's main operations are based in Menlo Park, CA.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Lawrence Otto Klein | President, Chief Executive Officer & Director | 1983 | $1,080,660 USD |
| Joana Goncalves | Chief Medical Officer | 1974 | $730,980 USD |
| Paul T. Quinlan | General Counsel & Secretary | 1963 | $730,980 USD |
| Alan Lada | VP of IR & Capital Markets | – | – |
| Arjun Agarwal | Senior Vice President of Finance & Treasurer | 1976 | – |
| Christopher Finch | Senior VP and Head of Business Development & Strategy | – | – |
| Laura Sandler | Chief Operating Officer | 1978 | – |
| Rajiv Panwar | Senior VP and Head of Chemistry, Manufacturing & Controls | – | – |